Palliative meflep therapy in advanced pancreatic cancer: Excellent response in a patient with her-2/neu amplification

Yee Chao, Jacqueline Ming Liu, Anna Fen YauLi, Ching Lin Perng, Chue Mei Tiu, Kuan Liang King, Li Tzong Chen, Wei Chun Lin, Chieh Lan, Jacqueline Whang-Peng

研究成果: 雜誌貢獻文章同行評審

2 引文 斯高帕斯(Scopus)


Introduction Patients with pancreatic cancer often present initially in advanced disease with many compromising factors, and yet they may still be responsive to chemotherapy. Aims The response of 23 patients with advanced pancreatic cancer to continuous infusion therapy was investigated. Methodology From September 1995 to February 1998, 23 patients with advanced pancreatic cancer, many with compromising factors, were treated with a MEFLEP regimen: biweekly 24-hour infusions of etoposide, 5-fluorouracil, leucovorin, epirubicin, and cisplatin, all given through an infusion pump, plus megestrol acetate, 160 mg/d, taken daily. A total of 145 courses were given. Overall response rate was 21% (4/19) for assessable chemo-naive patients; median survival for all 23 patients was 6 months; 22% of patients were alive at 1 year; and a clinical response benefit was attained in 35%. Results Toxicity was manageable; grade 3 or 4 leukopenia occurred in 1 patient each, 1 patient had fever and grade 3 infection, and grade 3 and 4 hyperammonemic encephalopathy developed in 3 and 1 patients, respectively. All four of the latter patients recovered uneventfully within 2 days of initiation of therapy. Nine patients were evaluated by fluorescence in situ hybridization for the Her-2/ neu oncogene, but for only one patient did amplification of the gene occur. She attained complete remission with treatment and lived for 26.7 months after diagnosis. Conclusion Biweekly MEFLEP is an active and manageable regimen for patients with advanced pancreatic cancer with compromised clinical status.
頁(從 - 到)e10-e14
出版狀態已發佈 - 1月 1 2002

ASJC Scopus subject areas

  • 緊急護理
  • 重症護理護理
  • 評估與診斷
  • 高級和專業護理


深入研究「Palliative meflep therapy in advanced pancreatic cancer: Excellent response in a patient with her-2/neu amplification」主題。共同形成了獨特的指紋。